Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Tom Ferguson"'
Autor:
Mohammed Al-Zubaidi, Elizabeth Liow, Dickon Hayne, Andrew D Redfern, Tom Ferguson, Steve McCombie, Pravin Viswambaram, Nat Lenzo, Richard Gauci
Publikováno v:
BMJ Open, Vol 12, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/08588462c0a448678e8048e2b36bf858
Autor:
Tom Ferguson, Martin Gore
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 2 (2010)
Externí odkaz:
https://doaj.org/article/0d4f0992ab7742b68853fb2f0ad8f4e1
Autor:
Dan Hoch, Tom Ferguson
Publikováno v:
PLoS Medicine, Vol 2, Iss 8, p e206 (2005)
Externí odkaz:
https://doaj.org/article/55a90b95c6604f14beabbcff8b377dff
Autor:
Elizabeth Chien Hern Liow, Nicole Swarbrick, Ian D. Davis, Dickon Hayne, Tom Ferguson, Andrew Moe, Andrew Redfern
Publikováno v:
BJU International. 128:9-17
Objectives This article presents the clinical trial protocol for a phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-
Autor:
Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Tian Zhang, Lei Xu, Kentaro Imai, Christian Heinrich Poehlein, Thomas Powles
Publikováno v:
Journal of Clinical Oncology. 41:679-679
679 Background: Adjuvant pembro prolonged disease-free survival (DFS) for patients (pts) with RCC at increased risk of recurrence after nephrectomy in the phase 3 KEYNOTE-564 study (NCT03142334). This post hoc exploratory analysis evaluated efficacy
Autor:
Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Howard Gurney, Lei Xu, Kentaro Imai, Jackie Rogerio, Thomas Powles
Publikováno v:
Journal of Clinical Oncology. 40:4512-4512
4512 Background: The randomized, double-blind, phase 3 KEYNOTE-564 study (NCT03142334) met its primary end point of disease-free survival with adjuvant pembrolizumab versus placebo after nephrectomy in patients with localized RCC who are at increased
Autor:
Piotr Tomczak, J. Hajek, Balaji Venugopal, Y.-H. Chang, Naveed Sarwar, David I. Quinn, M. Mahave, P. Zhang, J.-L. Lee, Naomi B. Haas, Toni K. Choueiri, Marine Gross-Goupil, Stefan Symeonides, T.B. Powles, Antoine Thiery-Vuillemin, P. Sawrycki, Tom Ferguson, S.H. Park, Jaqueline Willemann-Rogerio, T. Saretsky
Publikováno v:
Annals of Oncology. 32:S679-S680
Autor:
Tom Ferguson, Paul Weber
Publikováno v:
2009 Annual Conference & Exposition Proceedings.
Autor:
Dickon Hayne, Nicole Swarbrick, Stephen McCombie, Andrew Moe, Cynthia Hawks, Pravin Viswambaram, Ciara Conduit, Elizabeth Chien Hern Liow, Lisa Spalding, Jarrad Bothe, Tom Ferguson, Andrew James Martin, Ian D. Davis, Andrew David Redfern
Publikováno v:
Journal of Clinical Oncology. 40:483-483
483 Background: The sub-urothelial administration of checkpoint inhibitors has not been reported. This approach could be safer and more efficacious than systemic delivery for patients with non-muscle-invasive bladder cancer (NMIBC). Methods: This pha
Autor:
Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Lei Xu, Kentaro Imai, Jacqueline Willemann-Rogerio, David I. Quinn, Thomas Powles
Publikováno v:
Journal of Clinical Oncology. 40:290-290
290 Background: The double-blind, multicenter, randomized KEYNOTE-564 study (NCT03142334) is the first positive phase 3 study of adjuvant immunotherapy for patients (pts) with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence